首页> 外国专利> Controlled release sterile injectable aripiprazole formulation comprising a particulate aripiprazole having a mean particle size of 1-10 microns, administered once or twice a month and comprising a freeze-dried formulation, method of their production and uses thereof in treating schizophrenia

Controlled release sterile injectable aripiprazole formulation comprising a particulate aripiprazole having a mean particle size of 1-10 microns, administered once or twice a month and comprising a freeze-dried formulation, method of their production and uses thereof in treating schizophrenia

机译:控释无菌注射阿立哌唑制剂,其包含平均粒径为1-10微米的阿立哌唑颗粒,每月给药一次或两次,并包含冷冻干燥制剂,其制备方法及其在治疗精神分裂症中的用途

摘要

A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
机译:提供了一种控制释放的无菌冷冻干燥阿立哌唑制剂,其由具有所需平均粒径的阿立哌唑及其赋形剂形成,其在用水和肌内注射构成后,在至少约一个星期的时间内释放出阿立哌唑,直至大约八个星期。还提供了一种制备控释冷冻干燥阿立哌唑制剂的方法,以及使用上述制剂治疗精神分裂症的方法。

著录项

  • 公开/公告号IL175072A

    专利类型

  • 公开/公告日2015-06-30

    原文格式PDF

  • 申请/专利权人 OTSUKA PHARMACEUTICAL CO. LTD.;

    申请/专利号IL20060175072

  • 发明设计人

    申请日2006-04-20

  • 分类号A61K;A61K9/19;A61K31/496;A61K47/26;A61K47/38;A61P;

  • 国家 IL

  • 入库时间 2022-08-21 15:15:22

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号